Jennifer Michaelson net worth and biography

Jennifer Michaelson Biography and Net Worth

Insider of Cullinan Oncology

Jennifer is Chief Development Officer, Biologics at Cullinan.

Prior to joining Cullinan, Jennifer served as Senior Director and Executive Program Leader at Jounce Therapeutics, where she led the flagship ICOS antibody program, JTX-2011, from inception into Phase 2 development. An employee since company launch, Jennifer built and led multiple departments at Jounce, including Tumor Immunology, Pharmacology, and Preclinical Development. Jennifer was also a member of the Leadership Team at Jounce.

Previously, during her 10 year tenure at Biogen, Jennifer served as project leader for several monoclonal antibody and bispecific antibody programs in both the Oncology and Immunology therapeutic areas. Jennifer has also worked as a consultant at Third Rock Ventures for multiple stealth companies.

Jennifer received her B.A. in Biology from Princeton University and Ph.D from the Department of Cell Biology at Albert Einstein College of Medicine, and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.

What is Jennifer Michaelson's net worth?

The estimated net worth of Jennifer Michaelson is at least $624,174.87 as of November 25th, 2022. Dr. Michaelson owns 53,031 shares of Cullinan Oncology stock worth more than $624,175 as of February 5th. This net worth estimate does not reflect any other investments that Dr. Michaelson may own. Learn More about Jennifer Michaelson's net worth.

How old is Jennifer Michaelson?

Dr. Michaelson is currently 54 years old. There are 5 older executives and no younger executives at Cullinan Oncology. The oldest executive at Cullinan Oncology is Dr. Patrick A. Baeuerle Ph.D., Chief Scientific Officer, who is 64 years old. Learn More on Jennifer Michaelson's age.

How do I contact Jennifer Michaelson?

The corporate mailing address for Dr. Michaelson and other Cullinan Oncology executives is , , . Cullinan Oncology can also be reached via phone at 617-410-4650 and via email at [email protected] Learn More on Jennifer Michaelson's contact information.

Has Jennifer Michaelson been buying or selling shares of Cullinan Oncology?

Jennifer Michaelson has not been actively trading shares of Cullinan Oncology during the past quarter. Most recently, Jennifer Michaelson sold 4,000 shares of the business's stock in a transaction on Friday, November 25th. The shares were sold at an average price of $13.30, for a transaction totalling $53,200.00. Following the completion of the sale, the insider now directly owns 53,031 shares of the company's stock, valued at $705,312.30. Learn More on Jennifer Michaelson's trading history.

Who are Cullinan Oncology's active insiders?

Cullinan Oncology's insider roster includes Nadim Ahmed (Pres), Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Oncology's active insiders.

Are insiders buying or selling shares of Cullinan Oncology?

During the last twelve months, Cullinan Oncology insiders bought shares 3 times. They purchased a total of 1,035,486 shares worth more than $11,332,672.00. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 443,003 shares worth more than $4,775,189.28. The most recent insider tranaction occured on November, 25th when insider Jennifer Michaelson sold 4,000 shares worth more than $53,200.00. Insiders at Cullinan Oncology own 7.5% of the company. Learn More about insider trades at Cullinan Oncology.

Information on this page was last updated on 11/25/2022.

Jennifer Michaelson Insider Trading History at Cullinan Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/25/2022Sell4,000$13.30$53,200.0053,031View SEC Filing Icon  
9/27/2022Sell4,000$12.40$49,600.0053,031View SEC Filing Icon  
7/25/2022Sell8,000$14.51$116,080.0053,031View SEC Filing Icon  
10/18/2021Sell4,000$21.42$85,680.00View SEC Filing Icon  
9/20/2021Sell4,000$24.51$98,040.00View SEC Filing Icon  
See Full Table

Jennifer Michaelson Buying and Selling Activity at Cullinan Oncology

This chart shows Jennifer Michaelson's buying and selling at Cullinan Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Oncology Company Overview

Cullinan Oncology logo
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $11.77
Low: $11.36
High: $11.97

50 Day Range

MA: $11.12
Low: $9.72
High: $12.56

2 Week Range

Now: $11.77
Low: $7.30
High: $15.89


351,246 shs

Average Volume

146,318 shs

Market Capitalization

$536.83 million

P/E Ratio


Dividend Yield